Recruiting psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Recruiting is a registry status. The study team reports that the study is currently enrolling participants. Status is reported by the study team and can change.
Recruiting status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone. Eligibility and contact details are on each registry record, which is the place to check them.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 213 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 102 |
| MDMA | 21 |
| LSD | 10 |
| DMT | 6 |
| 5-MeO-DMT | 1 |
| Ayahuasca | 4 |
| Ketamine | 80 |
| Ibogaine | 1 |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 15 | 7% |
| Phase 1 | 54 | 25% |
| Phase 2 | 89 | 42% |
| Phase 3 | 19 | 9% |
| Phase 4 | 9 | 4% |
| Not applicable | 14 | 7% |
| Not reported | 13 | 6% |
Countries
Country is taken from the study's linked research site. 3 of 213 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 127 | 60% |
| Canada | 23 | 11% |
| Switzerland | 12 | 6% |
| Brazil | 8 | 4% |
| Israel | 8 | 4% |
| France | 5 | 2% |
| Netherlands | 4 | 2% |
| Austria | 3 | 1% |
| Australia | 3 | 1% |
| Germany | 3 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 178 |
| 2020 to 2023 | 28 |
| 2015 to 2019 | 6 |
| 2010 to 2014 | 1 |
Study design
- 200 interventional and 13 observational studies.
- Median planned or actual enrolment is 50 participants (range 2 to 50,000, across 213 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 70 |
| Trauma and PTSD | 22 |
| Pain and headache | 18 |
| Cancer and end of life | 15 |
| Other substance use | 13 |
| Suicidal thoughts | 11 |
| Alcohol use | 10 |
| Obsessive-compulsive disorder | 5 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07818564 | Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation | Recruiting | Phase 1 | United States | 2026-11 |
| NCT07721467 | Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | Recruiting | Phase 2 | United States | 2026-10 |
| NCT07868913 | Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department | Recruiting | Phase 2 | United States | 2026-09 |
| NCT07570654 | Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Recruiting | Phase 2 | United States | 2026-09 |
| NCT07716098 | A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression | Recruiting | Phase 3 | Taiwan | 2026-08 |
| NCT07562191 | Inhaled DMT for Major Depressive Disorder | Recruiting | Phase 2 | Brazil | 2026-08 |
| NCT07607938 | Psilocybin as a Novel Therapy for Residual Anhedonia | Recruiting | Phase 1 | United States | 2026-07 |
| NCT07610135 | Psilocybin Efficacy With or Without Pimavanserin Pretreatment | Recruiting | Phase 1 | United States | 2026-07 |
| NCT07680140 | Biomarker-Guided Antidepressant Selection | Recruiting | Phase 4 | United States | 2026-07 |
| NCT07747324 | Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial | Recruiting | Phase 1 | Brazil | 2026-07 |
| NCT07565493 | Psilocybin Administration With 5-HT1a Blockade | Recruiting | Early Phase 1 | United States | 2026-06 |
| NCT07226232 | Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression | Recruiting | Phase 3 | United States | 2026-06 |
| NCT07569198 | Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | Recruiting | Phase 2 | Canada | 2026-06 |
| NCT07638553 | Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms | Recruiting | Phase 3 | France | 2026-06 |
| NCT07639359 | Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients | Recruiting | Phase 2 | United States | 2026-05 |
| NCT06781697 | InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression | Recruiting | Phase 3 | Canada | 2026-05 |
| NCT07506395 | Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | Recruiting | Phase 1 | United States | 2026-05 |
| NCT07542145 | MDMA Assisted Therapy for BN | Recruiting | Phase 1 | United States | 2026-05 |
| NCT07569159 | MDMA Therapy in Veterans With PTSD | Recruiting | Phase 2 | United States | 2026-05 |
| NCT07610369 | The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease | Recruiting | Phase 2 | United States | 2026-05 |
| NCT07118839 | MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder | Recruiting | Phase 2 | United States | 2026-04 |
| NCT06066853 | MDMA-assisted Therapy for Fibromyalgia | Recruiting | Early Phase 1 | United States | 2026-04 |
| NCT07211438 | Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression | Recruiting | Phase 2 | Canada | 2026-04 |
| NCT07516405 | Safety and Tolerability Trial of Psilocybin in Healthy Older Adults | Recruiting | Phase 1 | United States | 2026-04 |
| NCT07563296 | KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury | Recruiting | Phase 2 | United States | 2026-04 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable